+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prevalence of dyslipidaemia in statin-treated patients in Ireland: Irish results of the DYSlipidaemia International Study (DYSIS)



Prevalence of dyslipidaemia in statin-treated patients in Ireland: Irish results of the DYSlipidaemia International Study (DYSIS)



Irish Journal of Medical Science 180(2): 343-349



Statins are proven to reduce cardiovascular risk; however, substantial risk remains in patients on statin therapy. Persisting dyslipidaemia is likely to play a contributory role. To assess the prevalence of persisting lipid abnormalities in patients treated with statins. DYSIS was a cross-sectional study of 22,063 patients in Europe and Canada. 900 Irish patients participated. All patients were ≥ 45 years and treated with statins for ≥ 3 months. Data were collected from the patients' records. ESC guidelines were used to classify risk and to define lipid levels. Mean age was 66.1 years with women representing 40.7%. 78.6% were high-risk patients; that is 53.9% with cardiovascular disease (CVD), 20.1% with diabetes and 15.9% with a SCORE risk ≥ 5%. Total cholesterol was not at goal in 34.4% of all patients. LDL-C was elevated in 30.8% of all patients and in 30% at high risk. Low HDL-C was found in 34.7% of high-risk patients compared to 16.9% of patients with an ESC score <5%. In diabetics without CVD, low HDL-C and elevated TGs were found in 46 and 44.3%, respectively. Despite statin therapy, a significant number of patients have persistent dyslipidaemia. While LDL-C targets are suboptimal in three out of ten patients, the prevalence of low HDL-C and high TGs in high-risk patients is greater than one in three. A more integrated approach to the treatment of patients with dyslipidaemia is warranted. Clinical trials are needed to assess the impact of therapies that raise HDL-C and lower elevated TGs.

(PDF emailed within 0-6 h: $19.90)

Accession: 055157388

Download citation: RISBibTeXText

PMID: 21400212

DOI: 10.1007/s11845-011-0702-8


Related references

Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS). Cardiovascular Journal of Africa 24(8): 330-338, 2014

Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS). International Journal of Clinical Practice 68(2): 180-187, 2015

Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS). Atherosclerosis 235(2): 463-469, 2015

Persistent lipid abnormalities in statin-treated patients: Portuguese diabetic subpopulation of the Dyslipidaemia International Study (DYSIS). Primary Care Diabetes 9(4): 283-289, 2016

Persistent dyslipidemia in Chinese patients treated with lipid-lowering drugs: interim results of the dyslipidaemia international study (DYSIS) China. European Heart Journal 34(Suppl 1): P4306-P4306, 2013

Prevalence of dyslipidaemia in patients treated with lipid-modifying drugs in the Netherlands. Part of the dyslipidaemia international survey. Netherlands Journal of Medicine 68(4): 168-174, 2010

Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabetic Medicine 28(11): 1343-1351, 2012

Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS). Canadian Journal of Cardiology 26(9): E330-E335, 2011

Prevalence of dyslipidemia in statin-treated patients in the Baltic states (Estonia, Latvia, and Lithuania): results of the Dyslipidemia International Study (DYSIS). Medicina 50(1): 44-53, 2016

Prevalence of lipid abnormalities among treated patients with stable CHD: The Dyslipidemia International Study (DYSIS) II South Korea results. Atherosclerosis 241(1): E131-E132, 2015

Randomised Study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Primary Results of the BERSON Clinical Trial. Diabetes, Obesity and Metabolism 2019, 2019

Results of the Dyslipidemia International Study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment. Plos One 9(1): E84350, 2014

The DYSlipidemia International Study DYSIS-Egypt A report on the prevalence of lipid abnormalities in Egyptian patients on chronic statin treatment. The Egyptian Heart Journal 65(3): 223-232, 2013

HIV-associated dyslipidaemia among HIV antibody-positive patients in Ireland: prevalence and management strategies. International Journal of Std and Aids 21(1): 75-76, 2010

Phytosterol supplementation in statin treated dyslipidaemia. Atherosclerosis 241(1): E188-E189, 2015